Drugs / TORL-3-600
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05948826 | Sep 2023 → Jun 2026 overdue | colorectal cancer | TORL Biotherapeutics, LLC | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TORL-3-600 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05948826 ↗ |
| Modality | Other / unclassified | “antibody drug conjugate” NCT05948826 ↗ |